{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-026097","form_type":"8-K","ticker":"VIVS","cik":"0001497253","company_name":"VivoSim Labs, INC.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.783278+00:00","generated_at":"2026-05-26T04:43:52.380132+00:00","sec_items":["1.01","3.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Organovo sells FXR program to Eli Lilly for $10M upfront; faces Nasdaq delisting","bullets":["Lilly to buy Organovo's FXR program for $10M upfront ($9M at close, $1M escrow) + up to $50M in milestones.","Lead asset FXR314, an oral FXR agonist for IBD, to be advanced to Phase 2 by Lilly.","Organovo faces Nasdaq delisting: stockholders' equity of $364K as of Dec 31, 2024, below $2.5M minimum.","Hearing before Nasdaq panel scheduled Feb 27, 2025; company may pursue reverse stock split to regain bid price compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-026097","json":"https://secwatch.observer/filing/0000950170-25-026097.json","markdown":"https://secwatch.observer/filing/0000950170-25-026097.md","text":"https://secwatch.observer/filing/0000950170-25-026097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1497253/000095017025026097/0000950170-25-026097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1497253/000095017025026097/onvo-20250219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:43:52.380132+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}